SCHEMBL9384154

SCHEMBL9384154

CC1CC(C)c2ccccc2N1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
ALDH1A1 P00352 2/20 0.55
KDM4E B2RXH2 1/20 0.46
ALOX15 P16050 1/20 0.46
HSD17B10 Q99714 1/20 0.46
BRD4 O60885 3/20 0.43
CREBBP Q92793 3/20 0.43
EP300 Q09472 1/20 0.43
MAPT P10636 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TSHR P16473 1/20 0.41
GFER P55789 1/20 0.41
HTR5A P47898 3/20 0.38
RAB9A P51151 1/20 0.38
AR P10275 1/20 0.36
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27473680 1.00 MEN1 (0.55) MEN1KMT2AALDH1A1KDM4EALOX15
SCHEMBL30499386 1.00 MEN1 (0.55) MEN1KMT2AALDH1A1KDM4EALOX15
SCHEMBL27473433 1.00 MEN1 (0.55) MEN1KMT2AALDH1A1KDM4EALOX15
SCHEMBL27473696 1.00 MEN1 (0.55) MEN1KMT2AALDH1A1KDM4EALOX15
SCHEMBL27476976 1.00 MEN1 (0.55) MEN1KMT2AALDH1A1KDM4EALOX15
SCHEMBL2608577 0.80 BRD4 (0.41) MEN1KMT2AALDH1A1BRD4CREBBP
SCHEMBL3458510 0.80 CREBBP (0.44) MEN1KMT2AALDH1A1BRD4CREBBP
SCHEMBL2607077 0.80 BRD4 (0.41) MEN1KMT2AALDH1A1BRD4CREBBP
SCHEMBL3458514 0.80 MAPT (0.43) MEN1KMT2AALDH1A1BRD4CREBBP
SCHEMBL18407439 0.77 AR (0.41) MEN1KMT2AALDH1A1KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024145483-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME HTG MOLECULAR DIAGNOSTICS, INC. (US) 2024-07-04 WO disclosed
CN-116272943-B Carbon-based nonmetallic catalyst and preparation method and application thereof 遵义医科大学 2024-06-11 CN disclosed
CN-116272943-A Carbon-based nonmetallic catalyst and preparation method and application thereof 遵义医科大学 2023-06-23 CN disclosed
US-9796678-B2 Method for manufacturing optically active compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-24 US disclosed
US-9796678-B2 Method for manufacturing optically active compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-24 US disclosed
US-20170022162-A1 METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-01-26 US disclosed
WO-2015141564-A1 METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND 住友化学株式会社 2015-09-24 WO disclosed
EP-0422178-B1 PYRIMIDINE DERIVATIVES ZENECA LTD (GB) 1994-10-05 EP disclosed
CN-1024793-C Pyrimiding derivatives ICI PLC (GB) 1994-06-01 CN disclosed
US-5223505-A PYRIMIDINE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-29 US disclosed
EP-0422178-A1 PYRIMIDINE DERIVATIVES. ICI PLC (GB) 1991-04-17 EP disclosed
CN-1047080-A Pyrimidine derivatives ICI PLC (GB) 1990-11-21 CN disclosed
WO-1990012790-A1 PYRIMIDINE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-11-01 WO disclosed
US-4014877-A MICROBIOCIDES RIKER LABORATORIES, INC. (US) 1977-03-29 US disclosed
US-4001243-A ANTI-MICROBIAL RIKER LABORATORIES, INC. (US) 1977-01-04 US disclosed
US-3985882-A ADMISTERING RIKER LABORATORIES, INC. (US) 1976-10-12 US disclosed
US-3969463-A MICROBIOCIDE RIKER LABORATORIES, INC. (US) 1976-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022162-A1 METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND C9, C5, PRMT7 MEN1 2508/4885KMT2A 663/4885ALDH1A1 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.